- A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 In Process GET IT
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
Proceedings of the National Academy of Sciences of the United States of America.
Times cited: 11